Supplements
boswellia prevents cancer
In plain terms: Does boswellia fight cancer?
Part of: 🧪 boswellia
No human evidence. Boswellic acids slow cancer cells in a dish, but nothing shows boswellia prevents or treats cancer in people. (It has been shown to reduce radiation-related brain swelling — an anti-inflammatory effect, not an anti-cancer one.)
📅 Last reviewed: 2026-07-15 ⓘ
Evidence ladder
How far up the ladder this claim has climbed. A high consensus on a low rung means "consistent so far," not "proven in people."
Top evidence so far: Animal studies (Animal)
How the studies fall
What the evidence shows
Lab-only. Boswellic acids show antiproliferative activity against cancer cells in vitro, but there is no human evidence that boswellia prevents or treats cancer. (Note: a human trial did show boswellia reduces radiation-related brain swelling in cancer patients — an anti-inflammatory effect, not an anti-cancer one.)
The evidence (13)
| Source | Grade | Stance | Quality | Finding |
|---|---|---|---|---|
| Qayum U et al 2026 · study_type: in-vitro | in-vitro | supports | low | Cell model: MDA-MB-231 breast cancer cells. Boswellia sacra stem/leaf essential oils showed moderate antiproliferative IC50 (~89-92 ug/mL), incidental to the study's primary antidiabetic/antimicrobial focus. |
| Eid AM et al 2026 · study_type: in-vitro | in-vitro | supports | low | Cell models: LX2, Hep-G2, Hela, MCF-7, 3T3. Boswellia sacra oil nanoemulgel showed anticancer cytotoxicity across five cancer cell lines with IC50 79-186 ug/mL, alongside antibacterial/anti-inflammatory activity. |
| Jamshidi-Adegani F et al 2026 · study_type: animal | animal | supports | moderate | Cell model SK-MEL-28 melanoma cells plus in vivo B16F10 mouse melanoma model. Incensole (Boswellia diterpene) induced p53-mediated apoptosis, inhibited migration, reduced tumor burden/metastasis and remodeled macrophage polarization in mice |
| Ragab W et al 2026 · study_type: in-vitro | in-vitro | supports | moderate | Cell model: HepG2 liver cancer cells. Frankincense aqueous extract combined with sorafenib produced strong synergistic cytotoxicity (CI=0.298), enhanced apoptosis/necrosis, autophagy activation, and reduced migration versus either agent alo |
| Khan SN et al 2026 · study_type: in-vitro | in-vitro | supports | low | Cell model: ovarian cancer lines A2780-S/A2780-CP and HUVEC. Synthetic triazole-metronidazole-boswellic acid hybrid derivatives showed enhanced selective cytotoxicity versus parent triterpenoids, with molecular docking to PARP6. |
| Kamalabadi-Farahani M et al 2025 · study_type: in-vitro | in-vitro | supports | low | Cell model: primary (4T1T) and brain-metastatic (4T1B) mouse breast cancer cell lines. Frankincense methanolic extract showed cytotoxic, apoptotic, and anti-metastatic (MMP-2/9 suppressing) effects, more pronounced in metastatic cells. |
| Al-Yasiry 2016 · Postepy Hig Med Dosw | observational | mixed | low | Review: anticancer activity of boswellic acids is described in vitro/in animals; no human prevention evidence. |
| Mazzio 2017 · Cancer Genomics Proteomics | in-vitro | mixed | low | In-vitro: boswellia altered gene expression / antiproliferative signalling in breast-cancer cells (preclinical). |
| Nigussie G et al 2026 · study_type: in-vitro | in-vitro | supports | low | Cell model: MCF-7 breast cancer cells. Boswellia neglecta stem methanol extract showed significant cytotoxicity (27% viability at 200 ug/mL) alongside antibacterial/antiviral/antioxidant effects. |
| Bonucci M et al 2025 · study_type: observational | observational | mixed | low | Human model: prospective non-randomized pilot in 72 glioblastoma patients; those adherent to an integrative regimen of polydatin, curcumin, AND Boswellia serrata (plus standard chemoradiotherapy) had longer median overall survival (25.4 vs |
| Fatima A et al 2026 · study_type: in-vitro | in-vitro | supports | moderate | Systematic literature review (PubMed/Web of Science/Scopus 2012-2025) of boswellic acids' anticancer activity, concluding potent activity against numerous cancer cell lines in preclinical (cell-line) studies, limited by bioavailability. |
| d10-1016-j-nxmate-2026-102712 2026 · Next Materials | in-vitro | supports | low | Cell model: HepG2 hepatocellular carcinoma cells. Pterostilbene-frankincense-essential-oil-loaded PLGA nanoparticles showed dose-dependent cytotoxicity (IC50 46.8 ug/mL) versus free pterostilbene (94.6 ug/mL). |
| Zhang J et al 2026 · study_type: in-vitro | in-vitro | supports | low | Cell model: MDA-MB-231 breast cancer cells. Boswellia serrata essential oil showed antiproliferative/apoptosis-inducing cytotoxicity (IC50 ~99-165 ug/mL) and synergized with doxorubicin. |
Disagree, or know a study we missed?
We grade by evidence, not opinions. The way to weigh in is to point us to a study we haven't cited (check the evidence table above first), or to flag a problem with one we have. Every submission is reviewed; if it holds up, the grade updates and shows in Science Changes Its Mind.
Opens a short form. You'll sign in with Google so submissions are tied to a real account — we don't display your identity, and we only accept a link we can verify (PubMed, DOI, ClinicalTrials.gov).
Educational only, not medical advice. Grades and scores reflect published evidence weighted by study design and quality; see the methodology.